Hemophilia B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Hemophilia B Market Outlook
Thelansis’s “Hemophilia B Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Hemophilia B treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Hemophilia
B Overview
Hemophilia
B is an uncommon congenital blood disorder characterized by a clotting factor
IX (FIX) deficiency, resulting in spontaneous bleeding episodes, particularly
in joints, and delayed blood clotting during external bleeding incidents.
Repeated joint bleeding can lead to long-term joint deterioration, physical
limitations, the necessity for joint replacements, chronic pain, and a
diminished quality of life (QoL). The level of circulating FIX determines the
severity of Hemophilia B (HB). The treatment approach revolves around FIX
replacement therapy, which can be administered either preventively to avert
bleeding episodes or reactively after a bleeding episode, known as “on-demand”
treatment. Prophylactic FIX therapy is regarded as the standard of care for
patients with severe and moderately severe HB. FIX is administered through
intravenous injections in either standard half-life (SHL) or extended half-life
(EHL) treatments every 2–3 or 7–14 days. However, the frequent infusions
required by FIX treatment can impose a significant treatment burden,
potentially affecting adherence and clinical effectiveness. The most prevalent
complication of hemophilia is attributed to bleeding episodes. Repeated
hemarthrosis leads to inflammation and hypertrophy of the synovial membrane,
ultimately causing destructive arthropathy. Other complications include
intracranial hemorrhages following minor trauma, hypovolemic shock events due
to bleeding in the iliopsoas muscle, and airway obstruction due to
retropharyngeal bleeding.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment